ALZpath and Alamar Biosciences Expand Alzheimer’s Blood Test Partnership
ALZpath and Alamar Biosciences have expanded their strategic agreement to include clinical diagnostics for Alzheimer’s disease, granting Alamar commercial rights to utilize the proprietary pTau217 antibody in blood-based diagnostic tests intended for clinical use, according to the companies. The broadened collaboration follows an initial agreement from February 2024 that integrated the antibody into research use … Read more